Age of amyloid onset, but not amyloid accumulation rate, differs across APOE‐e4 carriers vs. non‐carriers in three cohorts and three methods.

Autor: Betthauser, Tobey J., Bilgel, Murat, Koscik, Rebecca L., Jedynak, Bruno Michel, An, Yang, Jonaitis, Erin M, Christian, Bradley T., Engelman, Corinne D., Asthana, Sanjay, Wong, Dean F., Albert, Marilyn S., Resnick, Susan M., Johnson, Sterling C.
Zdroj: Alzheimer's & Dementia: The Journal of the Alzheimer's Association; Dec2021 Supplement S5, Vol. 17, p1-7, 7p
Abstrakt: Background: New methods have recently been developed to model longitudinal amyloid biomarkers in AD. This work compares three methods in three different cohorts, and investigates associations of APOE‐e4 status with amyloid onset age and amyloid accumulation rates. Method: Participants from ADNI (N=1213), BLSA (N=205) and WRAP (N=272) with available amyloid PET imaging and APOE genotype were included in the study (Table 1). Amyloid (A) burden was quantified using established methods (ADNI: BAI processed SUVR, WM reference region; BLSA: SRTM‐LRSC DVR, PVC, cerebellum GM reference region; WRAP: graphical analysis DVR, cerebellum GM reference region). Group‐based trajectory modeling (GBTM), ordinary differential equation‐Gaussian process (ODE‐GP) and sampled iterative local linear approximation (SILLA) methods were used to model longitudinal amyloid accumulation, estimate A+ onset age, and align amyloid values by years A+ for each cohort. Forward and backward SUVR/DVR prediction, estimated age of A+ onset, and associations of DVR/SUVR residuals with age, time from reference scan, and SUVR/DVR, were compared for each model and cohort. The impact of APOE genotype on A+ onset and amyloid PET accumulation trajectories was investigated using discrete rate sample, Kaplan‐Meier curves, and accelerated failure time models. Result: All methods produced similar amyloid vs. years A+ curves for each cohort (Figure 1) with most notable discrepancies occurring in the A‐ range. DVR/SUVR prediction performance was similar across methods and was better for retrospective vs. prospective prediction. Amyloid accumulation rates and trajectories were similar for APOE‐e4+ and APOE‐e4‐ genotypes (Figure 2). Kaplan‐Meier curves were different between the APOE groups (log‐rank test, p<0.005 for each test; Figure 3), with the e4+ group exhibiting earlier A+ onset ages compared to e4‐ (Table 2) for all methods and cohorts. Conclusion: This work demonstrates similar performance of three novel methods for modeling longitudinal amyloid PET burden and estimating individualized A+ onset age. Results suggest that APOE‐e4 status affects the A+ onset age, but not the rate of amyloid PET accumulation. Ongoing work is investigating potential differences in amyloid accumulation trajectories and A+ onset age between APOE genotypes (e.g. e3e3, e3e4, e4e4,...) and is investigating relationships between A+ onset, APOE genotype and onset of cognitive impairment. [ABSTRACT FROM AUTHOR]
Databáze: Supplemental Index